Kezar Life Sciences, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 7.29 USD (At close: May 8, 2026) · Market cap 53.86M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States. The company’s lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b/2 clinical trials in systemic lupus erythematosus. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Details
| Name | Kezar Life Sciences, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 9 |
| Founded | 2015 |
| Ipo Date | 2018-06-21 |
| Ceo | Christopher Kirk |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US49372L2097 |
| Cusip | 49372L100 |
| Cik | 0001645666 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Dr. Christopher J. Kirk Ph.D. | Co-Founder, Chief Executive Officer and Director |
| John Franklin Fowler | Co-Founder and Director |
| Mark Schiller | Chief Operations Officer |
| Dr. Jack Taunton Ph.D. | Co-Founder |
| Pichi Chiang | Senior Vice President and Controller |
Contact
| Address | 4000 Shoreline Court, Suite 300, South San Francisco, California 94080, United States |
| Phone | 650 822 5600 |
| Website | https://www.kezarlifesciences.com |